Full Text View
Tabular View
No Study Results Posted
Related Studies
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis (TERMS)
This study has been completed.
Study NCT00245622   Information provided by Opexa Therapeutics, Inc.

First Received on October 20, 2005.   Last Updated on June 27, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Interventions listed in this trial
Tovaxin Autologous T cell vaccine
Placebo
Sponsors listed in this trial
Opexa Therapeutics, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services